G-L Archives | Report Store | Pharma intelligence

show blocks helper

Sort by Default

Display 15 Products per page

Ipatasertib
Read More
Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt.
February 26, 2020
Find out more
Lynparza
Read More
Lynparza (olaparib; AstraZeneca) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor. The PARP enzyme plays a central role in a number of cellular processes involved in cellular homeostasis.
February 26, 2020
Find out more
Keytruda
Read More
Keytruda is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells.
February 26, 2020
Find out more
Halaven
Read More
Halaven (eribulin mesylate; Eisai) is a synthetic macrocyclic ketone analog of halichondrin B that acts as a tubulin depolymerizer and functionally inhibits tumor cell proliferation with arrest in the G2-M phase of cell growth. B
February 26, 2020
Find out more
Juxtapid
Read More
Juxtapid (lomitapide mesylate) is a novel, first-in-class microsomal triglyceride transfer protein (MTP) inhibitor marketed by Aegerion.
November 20, 2019
Find out more
Inclisiran
Read More
Inclisiran (The Medicines Company/Alnylam Pharmaceuticals) is a systemically delivered siRNA therapeutic targeting mRNA for PCSK.
November 20, 2019
Find out more
Imfinzi
Read More
Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1).
September 9, 2019
Find out more
Lenvima
Read More
Lenvima (lenvatinib; Eisai/Novartis/Merck & Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR).
September 9, 2019
Find out more
Juluca
Read More
Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson & Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral suppression.
June 28, 2019
Find out more
leronlimab
Read More
Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into host cells.
June 28, 2019
Find out more
Isentress
Read More
Isentress (raltegravir; Merck & Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.
June 28, 2019
Find out more
Genvoya
Read More
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Lexapro
Read More
Lexapro (escitalopram; Allergan/Lundbeck/Mitsubishi Tanabe/Mochida) is a selective serotonin reuptake inhibitor, and acts by blocking the re-uptake of serotonin.
March 29, 2019
Find out more
Latuda
Read More
Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia symptoms.
March 29, 2019
Find out more
Inlyta
Read More
Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.
March 6, 2019
Find out more

G-L

Ipatasertib

Lynparza

Keytruda

Halaven

Juxtapid

Inclisiran

Imfinzi

Lenvima

Juluca

leronlimab

Isentress

Genvoya

Lexapro

Latuda

Inlyta